Hutchison China MediTech Limited (Chi-Med) has kicked off today in Australia the first-in-human (FIH) Phase I clinical testing of inhibitor HMPL-453, for fibroblast growth factor receptor signaling pathway, which forces tumor growth.
HMPL-453 could be the first approved therapy to particularly target this problem.
In pre-clinical studies, HMPL-453 eprformed superior potency and better kinase selectivity as compared to other drugs in the same class, as well as a favorable safety profile.